Form 4: Terns Pharma Director Opts for Stock Over Cash

Terns Pharmaceuticals director Heather D Turner elected to receive stock options valued at $45,000 in lieu of her 2026 cash retainer.

Summary

• Heather D Turner, a Director at Terns Pharmaceuticals, Inc. (TERN), acquired 1,697 stock options.
• The options were granted on February 1, 2026, with an exercise price of $34.6 per share.
• This option grant was made pursuant to the Issuer's Non-Employee Director Compensation Policy.
• The options were received in lieu of a $45,000 cash retainer fee for the year 2026.
• The options will vest at a rate of 1/12th of the total shares monthly, starting from January 1, 2026, and will be fully vested by January 1, 2027.
• The expiration date for these stock options is January 31, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it indicates a director's commitment to the company's long-term performance through equity ownership, which is generally favorable for shareholder alignment.

Positives

• The election by a director to receive equity compensation instead of cash aligns their interests more closely with long-term shareholder value.
• Utilizing stock options for director compensation helps conserve the company's cash reserves.

Negatives

• The issuance of new stock options, while minor in this instance, can lead to potential dilution for existing shareholders upon exercise.

Future Outlook

The granted stock options will vest monthly, with 1/12th of the total shares vesting on each monthly anniversary from January 1, 2026, leading to full vesting by January 1, 2027.

Industry Context

StockSavvy.ai notes that providing equity compensation, such as stock options, to non-employee directors is a common practice across the biotechnology and pharmaceutical industries. This approach is often adopted by companies to align director incentives with long-term shareholder value creation and conserve cash, reflecting a broader trend in corporate governance.

Comparison to Industry Standards

• The practice of offering stock options in lieu of cash retainers for non-employee directors is standard across many publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• Comparable companies such as Amgen or Gilead Sciences frequently utilize equity-based compensation to incentivize directors and align their financial interests with company performance.
• The vesting schedule of 1/12th monthly over a year is a typical structure for such grants, ensuring continued engagement and commitment from the director.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of director interests with shareholder value creation. Minor potential for future dilution upon option exercise.
• Company: Conserves cash that would otherwise be paid as a retainer, potentially freeing up capital for other operational needs.

Next Steps

• The stock options will continue to vest monthly until fully vested on January 1, 2027.

Key Dates

Keywords

Terns Pharmaceuticals, TERN, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Compensation, Biotechnology, Pharmaceuticals